Actively Recruiting
Vivatlac in Irritable Bowel Syndrome II (ViIBS2)
Led by The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz · Updated on 2025-12-15
200
Participants Needed
3
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Multi-center,randomized, double-blind, placebo-controlled, 36 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) in IBS patients
CONDITIONS
Official Title
Vivatlac in Irritable Bowel Syndrome II (ViIBS2)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with Irritable Bowel Syndrome using the IBS questionnaire for Health Care Providers of the World Global Gastroenterology Organization
- IBS-Severity of Symptoms Scale (IBS-SSS) score of 175 or higher
You will not qualify if you...
- Currently taking or have taken probiotics within the last 3 months
- Currently taking or have taken antibiotics within the last 3 months
- Having a severe illness such as malignancies, uncontrolled hypertension or diabetes, liver, kidney, or heart problems, serious neurological disorders, psychosis, respiratory disorders like asthma or COPD, or thyroid disorders
- Having chronic bowel disorders other than IBS, including inflammatory bowel disease, gastroenteritis, stomach or duodenal cancer, or celiac disease
- Pregnant, breastfeeding, or planning pregnancy within the next 9 months
- Diagnosed with lactose intolerance
- Using motility drugs or dietary fiber supplements within 2 weeks before study start
- Taking anti-coagulant medication
- Participated in another clinical trial within the last 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
District Hospital Jarocin
Jarocin, Poland, 63-200
Actively Recruiting
2
GP Clinic Spitalna
Jarocin, Poland, 63-200
Actively Recruiting
3
GP Clinic Wroclawska
Jarocin, Poland, 63-200
Actively Recruiting
Research Team
J
Jacek Piatek, Prof. Dr.
CONTACT
H
Henning Sommermeyer, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here